New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

In June, asthma care and respiratory medicine were marked by pivotal updates, including new data reinforcing best practices and highlighting potential therapeutic breakthroughs across multiple respiratory and immune-mediated conditions. This month’s news underscores the importance of optimizing asthma management strategies, advancing biologic therapies for chronic airway diseases, and exploring novel interventions for challenging pulmonary disorders.

Among the key developments, a comprehensive meta-analysis confirmed the dangers of short-acting beta-agonist (SABA) overuse, strengthening support for inhaled corticosteroid-based regimens. In chronic rhinosinusitis with nasal polyps and coexisting asthma, dupilumab proved superior to omalizumab in the EVEREST trial, setting a new benchmark for biologic therapy. Positive interim and phase 2b results from trials of efzofitimod and treprostinil palmitil inhalation powder demonstrated encouraging efficacy signals for systemic sclerosis-related interstitial lung disease and pulmonary arterial hypertension, respectively.

Check out this July 2025 pulmonology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

Examining APP-Led Endobronchial Valve Therapy for COPD, with Haley Hoy, PhD, CRNP

 spoke with Haley Hoy, PhD, CRNP, who discussed the critical role advanced practice practitioners (APPs) can play in improving COPD care, especially in rural outreach settings where they help expedite diagnoses, referrals, and access to treatments like endobronchial valve therapy.
2. 

Genentech (Roche)’s Astegolimab Shows Mixed Data for COPD

Genentech reported mixed phase 3 results for astegolimab in COPD, with the ALIENTO trial showing a statistically significant 15.4% reduction in annualized exacerbation rate at 52 weeks, while the ARNASA trial failed to meet its primary endpoint despite a similar 14.5% reduction. Neither trial found no new safety signals, but the inconsistent efficacy results may challenge astegolimab’s regulatory path.

 Heart Failure, AF, and Mortality More Common After RSV Than UTI or Flu Hospitalizations in Older Adults

A retrospective cohort study of adults ≥65 years in Ontario found that 18.5% of those hospitalized with RSV experienced a cardiovascular event within one year, higher than those hospitalized for influenza, UTI, or fracture. RSV hospitalizations were associated with significantly higher risks of subsequent heart failure, atrial fibrillation, ICU admission, and longer hospital stays.

 New Consensus Aims to Align Post-COVID CT Imaging Practices


A multisociety consensus statement recommends standardized CT imaging practices for post–COVID-19 residual lung abnormalities. Key guidance includes limiting chest CT to patients with persistent symptoms at least 3 months post-infection, using low-dose protocols, and avoiding terms like “interstitial lung abnormality” in favor of “post–COVID-19 residual lung abnormality” to prevent unnecessary workups for fibrosis.

The Biologic Era in COPD: What Mepolizumab Approval Means for Exacerbation Control


Joseph Khabbaza, MD, Nikita Desai, MD, and Eric Costanzo, MD, discussed the clinical impact of the FDA approval of mepolizumab for eosinophilic COPD, highlighting its potential to reduce exacerbations and lower corticosteroid dependence in a traditionally treatment-resistant population. Supported by the phase 3 MATINEE trial, mepolizumab marks a shift toward personalized care in COPD, offering a targeted option for the estimated 40% of patients with type 2 inflammation and drawing parallels to the evolution seen in asthma management.

Articles

June brought significant advancements in asthma care and respiratory medicine, emphasizing the importance of optimizing management strategies and exploring novel interventions. Key developments included a meta-analysis confirming the risks of SABA overuse, supporting inhaled corticosteroid regimens. The EVEREST trial highlighted dupilumab's superiority over omalizumab for chronic rhinosinusitis with nasal polyps and asthma. Promising results from efzofitimod and treprostinil palmitil trials showed efficacy for systemic sclerosis-related interstitial lung disease and pulmonary arterial hypertension. These updates underscore the ongoing evolution in biologic therapies and personalized care approaches.

July 2025 saw a number of updates in COPD management and new research on RSV and COVID.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

5 Rheumatology Headlines You Missed in July 2025

Over the past decade, the understanding and management of severe hypertriglyceridemia syndromes—particularly 

(FCS) and multifactorial chylomicronemia syndrome (MCS)—have begun to shift. Historically treated with extreme dietary fat restriction and off-label lipid-lowering therapies of limited efficacy, these rare disorders were often misdiagnosed or poorly understood outside of specialized lipid clinics. FCS, a monogenic condition marked by persistent chylomicronemia (PC) and risk of recurrent pancreatitis, has been particularly underserved, while MCS, far more prevalent but less well characterized, continues to be underrecognized in clinical practice.

In recent years, however, progress in genetic diagnostics, growing awareness among endocrinologists and lipid specialists, and targeted drug development have changed the trajectory of care. Investigational therapies targeting key regulators such as APOC3 and ANGPTL3 have shown promise in early-phase studies, and ongoing trials reflect a more precise, mechanism-based approach to treatment. As the field pushes toward better stratification and tailored intervention, clinicians are increasingly engaged in conversations about bridging gaps in diagnosis, expanding access to specialty care, and defining meaningful outcomes for patients whose conditions have long been managed at the margins of standard lipid care.

 convened a clinical forum led by Eliot Brinton, MD, President and Director of the Utah Lipid Center, to delve into the clinical, diagnostic, and treatment complexities of MCS and FCS.

The forum outlined how MCS is often underdiagnosed and misunderstood, while FCS, although rarer, poses a more severe and genetically defined lipid disorder that leads to significant clinical challenges. They stressed that misdiagnosis remains common due to overlapping symptoms and non-specific presentations, particularly in emergency settings with acute pancreatitis.

"Although diet works like you also said, there's some people where they're just they're not able to do the diet and it is just not feasible for them. And so to have powerful drugs that are not niacin and not going to make their glucose go up... I think it's nice to have modern, newer medications to help," a panelist said. "One concern is how can drugs like this be expanded to more than just the severe patients with alarm features like recurrent pancreatitis and hospitalizations, family history? How can we expand it out more to just patients with really high triglycerides?"

Panelists highlighted the inadequacies in current therapeutic options, particularly the lack of approved treatments for FCS. Extreme dietary restrictions remain a mainstay, which adds psychological and social burden to the disease. They  emphasized the unmet need for novel therapies that can target specific genetic pathways like APOC3 and ANGPTL3, the role of healthcare provider education, and the importance of improving diagnostic and care pathways for affected patients.

"The clinical or functional FCS and the PC with alarm features, to me, seem the same. I think that would be definitely those folks would benefit from these new drugs... To me, where these drugs are really going to be beneficial are for the people with the polygenic MCS who have these recurrent pancreatitis episodes. And those are the ones who just keep going in the hospital, and it's a huge struggle, and we can't use other agents like - I'm going to go off grid here and say GLP-1 receptor agonists. And so that's where these drugs, I think, are going to be really promising," a panelist said. "I think a big barrier is obtaining these drugs because even for the few people that I have on the available drug, Olezarsen, you have to jump through multiple hoops, you have to call all these people, answer the phone when they're calling. And for education, that's going to be a big barrier."

Izar MC, Fonseca FAH. Novel Therapeutics for Familial Chylomicronemia Syndrome. 

. 2025;27(1). doi: 0.1007/s11883-025-01295-x

Recent advancements in the understanding and management of severe hypertriglyceridemia syndromes, such as familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS), have shifted the treatment landscape. Historically reliant on extreme dietary restrictions and off-label therapies, these conditions were often misdiagnosed. Progress in genetic diagnostics and targeted drug development, focusing on regulators like APOC3 and ANGPTL3, offers new hope. Despite these advances, challenges remain in diagnosis, access to care, and the development of effective therapies, particularly for FCS, which lacks approved treatments.

Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.

Dyslipidemia

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

From Misdiagnosis to Management: Understanding the Full Burden of MCS and FCS

Nada Elbuluk, MD, MSc, is a dermatologist in California. 

Esther E. Freeman MD, PhD, is Associate Professor of Dermatology at Harvard Medical School and a board-certified dermatologist.

Karolyn (Kari) Wanat, MD, is currently on faculty as an Associate Professor at the Medical College of Wisconsin in Milwaukee where she practices complex medical dermatology, inpatient consults, and dermatopathology and is the Residency Program Director.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Skin of Color Savvy: Improving Global Access in Dermatology with GLODERM

This special Clinical Episode of the Skin of Color Savvy: The Art and Science of Treating Patients of Color features an illuminating conversation between Nada Elbuluk, MD, current president of the 

, and esteemed dermatologists and global health leaders Esther Freeman, MD, PhD, and Karolyn Wanat, MD. Freeman is known for her work as Associate Professor of Dermatology at Harvard Medical School and Wanat as an Associate Professor at the Medical College of Wisconsin in Milwaukee.

Together, the Elbuluk, Wanat, and Freeman explore the fast-growing field of global health dermatology, the work of the International Alliance for Global Health Dermatology (GLODERM), and an exciting new collaboration between GLODERM and SOCS. Freeman begins by defining global health dermatology as the practice of dermatology in under-resourced settings, whether domestic or international.

Freeman, GLODERM's co-founder, emphasizes that global health is not limited to crossing borders—it is about ensuring access to dermatologic care wherever inequities exist. Wanat, the current chair of GLODERM, describes the group’s mission: advancing global skin health for all by building partnerships across clinicians, trainees, and communities.

The conversation outlines GLODERM’s exponential growth since its founding in 2017—from a grassroots effort by 10 dermatologists to an international network of nearly 3000 members across over 60 countries. Freeman and Wanat explain how GLODERM fits into the broader ecosystem of international dermatologic organizations, operating within the International Foundation for Dermatology (IFD), the humanitarian arm of the International League of Dermatological Societies (ILDS).

A highlight of the discussion is the recently passed World Health Assembly resolution designating skin disease as a global public health priority—a milestone Freeman helped achieve after years of collaboration with the World Health Organization (WHO). Backed by multiple sponsoring countries, the resolution formally acknowledges the critical health burden posed by skin disease worldwide and urges ministries of health to address it through funding and policy action.

The episode also explores GLODERM’s flagship mentorship program, which pairs emerging dermatology leaders in low-resource settings with international mentors. Wanat and Freeman share real-world examples of how mentees have launched transformative programs in countries like Burundi, Ecuador, and St. Lucia, from creating albinism outreach initiatives to launching new residency programs and public health campaigns.

Education is another pillar of GLODERM’s work. The organization hosts global webinars, scientific symposia, and podcasts to amplify expertise and support knowledge exchange. These efforts led to the creation of SEED (Supporting Emerging Education in Dermatology), a peer network of educators working to build new dermatology training programs in countries such as Rwanda, Fiji, and Ethiopia.

Freeman and Wanat emphasize the synergy between GLODERM and SOCS, pointing to shared priorities around mentorship, advocacy, and educational equity. Together, the organizations plan to co-develop webinars, support SOCS’s new global council and SOC Serves platform, and broaden outreach to underserved communities around the world.

They conclude the episode on an optimistic note, pointing to the remarkable momentum building around global health dermatology. What was once a niche passion is now a growing field with a thriving infrastructure, a deepening pipeline of young leaders, and an expanding global reach—all anchored by the belief that skin health is essential to overall health and that access to care should be universal.

To learn more about the Skin of Color Society's (SOCS) mentorship programs and initiatives, visit 

Editor’s note: This podcast summary was edited with the help of artificial intelligence tools.

Videos

This clinical episode of Skin of Color Savvy highlights the the work of the International Alliance for Global Health Dermatology (GLODERM) and a new collaboration between GLODERM and SOCS.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: Vanderbilt University Medical Center

A recent study revealed that the longer patients with 

remained on dupilumab, the more their specific IgE (sIgE) levels reduced.

“Our study showed that dupilumab induced a significant reduction in food sIgE in pediatric patients with [atopic dermatitis] and concomitant [food allergy] over a median of 17 months,” wrote investigators, led by Alexander G. Emerson, MD, from the division of pediatric allergy, immunology, & pulmonary medicine at Monroe Carell Jr. Children’s Hospital, Vanderbilt University Medical Center.

 “This is in keeping with prior studies in adult patients with atopic dermatitis and food allergy and in patients with aeroallergen sensitization.”

The US Food and Drug Administration (FDA) approved dupilumab, a monoclonal antibody that blocks IL-4 receptor alpha (IL4Rα) to reduce inflammation, for multiple atopic and inflammatory conditions. Approved indications include atopic dermatitis, bullous pemphigoid, chronic spontaneous urticaria, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

Dupilumab is not indicated for food allergy, an atopic disorder rising in prevalence. Research has begun examining dupilumab as both a monotherapy and an adjunct to oral immunotherapy for the treatment of peanut allergy in children. A phase 2 multicenter, single-arm study of dupilumab as a monotherapy for peanut allergy desensitization found only 8% of participants could pass a 24-week double-blind, placebo-controlled oral food challenge of dupilumab 444 mg taken every 2 weeks.

In this retrospective study, investigators sought to assess the effect of dupilumab on food allergy by reviewing electronic medical records of 60 children aged 6 months to 18 years receiving dupilumab at a single center for their comorbid atopic dermatitis.

All patients were treated at Vanderbilt University Medical Center between June 2019 and July 2024. During routine clinical care, patients received a skin prick test, SIgE, and oral food challenges.

Linear regression analyses showed that with each additional month of dupilumab treatment, sIgE levels reduced by 0.3% (95% confidence interval [CI] –0.8% to –0.4%, 

 < .001). The overall mean percentage decrease in patients receiving dupilumab was greater for sIgE (-66.4%; 95% CI, -74.9% to -57.9%) compared to the skin prick test (-28%; 95% CI -39.4% to -16.5%) (

Patients receiving dupilumab had significant percent decreases in SIgEs for 6 foods: almond, Brazil nut, cashew, egg, peanut, and walnut—showed statistically significant percent decreases in SIgEs.

“Only 2 foods (hazelnut and pecan) did not show a statistically significant reduction in sIgE with a 95% CI crossing slightly over 0,” investigators noted.

 “We attribute this finding to skewing by outliers in whom sIgE increased to these nuts after the start of dupilumab.”

Only 3 foods—almond, pecan, and walnut—showed significant decreases in skin prick test wheal size. The study showed that increased time on dupilumab was not linked to a statistically significant change in skin prick test wheal size (0.1%; 95% CI, -0.6% to 0.7%; 

Among 50 food challenges that took place, 38 (76%) passed (i.e., no reaction), which was a similar pass rate to previous cohorts. Participants who passed either received dupilumab every 4 weeks (n = 13) or every 2 weeks (n = 11).

Moreover, 8% resulted in Consortium for Food Allergy Research (CoFAR) grade 1 – 2 allergic reactions treated with antihistamines only, and 12% resulted in anaphylaxis (CoFAR grade 3 – 4 severity).

 Four patients received epinephrine; all of them had ingested more than half of the challenge goal before a reaction was observed. A single accidental home exposure to both baked egg and milk in a cookie, counting as 2 challenges (4%), led to oral itching.

“In this retrospective review of children receiving dupilumab for [atopic dermatitis] with comorbid [food allergy], we showed that [skin prick test] wheal size to food allergens is more preserved over time on dupilumab therapy while sIgE values decline with continued dupilumab use,” investigators concluded.

 “Interestingly, this finding has also been observed in aeroallergen testing with dupilumab use in CRSwNP and suggests that [skin prick test] may potentially be a more reliable marker of ongoing sensitization to follow in patients’ food allergy clinical course.”

Emerson AG, Krantz MS, Robison RG. Food Allergy Clinical Course in Children and Adolescents Treated with Dupilumab for Atopic Dermatitis. 

. Published online July 27, 2025. doi:10.1016/j.anai.2025.07.023

Smith, T. FDA Approves Dupilumab (Dupixent) for Bullous Pemphigoid in Adult Patients. HCPLive. June 20, 2205. 

https://www.hcplive.com/view/fda-approves-dupilumab-dupixent-for-bullous-pemphigoid-in-adult-patients

Smith, T. FDA Approves Dupilumab (Dupixent) for Chronic Spontaneous Urticaria. HCPLive. April 18, 2025. 

https://www.hcplive.com/view/fda-approves-dupilumab-dupixent-for-chronic-spontaneous-urticaria

Smith, T. FDA Approves Dupilumab (Dupixent) for Treatment of COPD. HCPLive. September 27, 2024. 

https://www.hcplive.com/view/fda-approves-dupilumab-dupixent-for-treatment-of-copd

Smith, T. FDA Approves Dupilumab for Adolescents with Chronic Rhinosinusitis with Nasal Polyps. HCPLive. September 13, 2024. 

https://www.hcplive.com/view/fda-approves-dupilumab-for-adolescents-chronic-rhinosinusitis-with-nasal-polyps

Butera, A. FDA Approves Dupilumab for Eosinophilic Esophagitis. HCPLive. May 20, 2022. 

https://www.hcplive.com/view/fda-approves-dupilumab-for-eosinophilic-esophagitis

Sindher SB, Nadeau KC, Chinthrajah RS, Leflein JG, Bégin P, Ohayon JA, et al. Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study. Allergy. 2025 Jan;80(1):227-237. 10.1111/all.16404. Epub 2024 Dec 14. PMID: 

https://pubmed.ncbi.nlm.nih.gov/39673452/

A study demonstrated that prolonged use of dupilumab in pediatric patients with atopic dermatitis and food allergies significantly reduced specific IgE levels. Dupilumab, a monoclonal antibody approved for various atopic and inflammatory conditions, is not yet indicated for food allergies. The retrospective study reviewed 60 children, revealing a 66.4% decrease in sIgE levels with dupilumab treatment. While skin prick test wheal sizes remained stable, food challenges showed a 76% pass rate. The findings suggest that skin prick tests may be a more reliable marker for ongoing sensitization in food allergies.

In a study of children with food allergy and atopic dermatitis, longer dupilumab use was associated with significantly lower food-specific IgE levels.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Dupilumab Reduces Food-Allergen sIgE in Children with Atopic Dermatitis

In July, a wave of new data advanced the understanding and treatment of psoriatic arthritis, systemic lupus erythematosus, and fibromyalgia, with several therapies showing potential to reshape clinical care. Tildrakizumab and deucravacitinib both met primary endpoints in phase 3 PsA trials, while guselkumab became the first IL-23 inhibitor to demonstrate inhibition of structural joint damage progression. Zasocitinib, a TYK2 inhibitor, showed strong efficacy across ACR and skin endpoints in PsA with a favorable safety profile, and dapirolizumab pegol significantly improved disease activity and fatigue in SLE, doubling rates of low disease activity versus standard of care. In fibromyalgia, GLP-1 receptor agonists were associated with reduced opioid use and symptom burden in a large matched cohort analysis, pointing to a novel therapeutic approach beyond traditional analgesics.

Check out this July 2025 rheumatology month in review for a recap of HCPLive’s coverage of the top news and research from the past few weeks:

DZP Significantly Improves Disease Activity, Fatigue in People With SLE

Dapirolizumab pegol (DZP) significantly improved disease activity and fatigue in patients with moderate-to-severe SLE, with 40.9% achieving low disease activity at Week 48 compared to 19.6% on standard of care (SOC) alone (

 <.0001), according to phase 3 PHOENYCS GO trial data presented at EULAR 2025.
These findings highlight DZP’s potential to achieve key treat-to-target goals such as LLDAS and DORIS remission while minimizing glucocorticoid use.

Zasocitinib Data Demonstrates Efficacy of TYK2 Inhibition for Psoriatic Arthritis

In a phase 2b trial, zasocitinib 30 mg and 15 mg significantly improved ACR20 responses at week 12 in patients with active psoriatic arthritis (54.2% and 53.3%, respectively, vs. 29.2% with placebo; 

 = .002), with additional numeric gains seen in ACR50, ACR70, PASI 75, and MDA rates. The drug’s safety profile remained manageable with no new safety signals, supporting TYK2 inhibition as a promising, targeted, and potentially safer oral treatment pathway for PsA; phase 3 trials are currently underway.

Fibromyalgia Pain: The Next Frontier for GLP-1 RAs?

In a large propensity-matched cohort study, GLP-1 receptor agonists were associated with a significantly lower risk of opioid use in fibromyalgia patients (OR, 0.600; risk difference, -12.6%; 

 <.001), along with reductions in fatigue, malaise, and chronic pain symptoms. Patients receiving GLP-1 RAs also showed decreased reliance on ongoing fibromyalgia care (OR, 0.512; risk difference, -16.6%; 

 <.001), though BMI and A1c improvements were more pronounced in the non-GLP-1 RA group.

TYK2 Inhibitor Deucravacitinib up for FDA Review for Psoriatic Arthritis

The FDA accepted Bristol Myers Squibb’s sNDA for deucravacitinib in active psoriatic arthritis with a PDUFA date of March 6, 2026, based on phase 3 POETYK PsA trials showing 54.2% of patients achieved ACR20 at week 16 versus 34.1% with placebo (

 <.0001). The TYK2 inhibitor also significantly improved PASI 75 response, physical function, fatigue, and radiographic progression, with no new safety signals and a low rate of serious adverse events.

Pivotal Tildrakizumab Trials Meet Endpoint for Psoriatic Arthritis

Tildrakizumab 100 mg met its primary endpoint in both INSPIRE-1 and INSPIRE-2 phase 3 trials by significantly improving ACR20 response rates at week 24 versus placebo (

 <.05) in patients with active psoriatic arthritis. The IL-23 inhibitor also showed improvements in ACR50, ACR70, and PASI75 with a safety profile consistent with previous psoriasis trials, reinforcing its potential as a PsA treatment option.
6. 

J&J Seeks New Guselkumab Label Reflecting Inhibition of PsA Joint Damage

Johnson & Johnson has submitted an sBLA to expand guselkumab’s label to include new phase 3b APEX data showing significant inhibition of structural joint damage progression in active psoriatic arthritis, with mean modified vdH-S score changes of 0.55 (Q4W) and 0.54 (Q8W) versus 1.35 with placebo (

Recent advancements in rheumatology have highlighted promising therapies for psoriatic arthritis, systemic lupus erythematosus, and fibromyalgia. Tildrakizumab and deucravacitinib have shown efficacy in PsA trials, while guselkumab demonstrated inhibition of joint damage progression. Zasocitinib, a TYK2 inhibitor, exhibited strong efficacy and safety in PsA. Dapirolizumab pegol significantly improved SLE outcomes, achieving higher rates of low disease activity. GLP-1 receptor agonists in fibromyalgia were linked to reduced opioid use and symptom burden, suggesting a novel therapeutic approach. These findings may reshape clinical care and treatment strategies.

The rheumatology month in review emphasizes new research in psoriatic arthritis treatments and data from EULAR 2025.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

6 Rheumatology Headlines You Missed in July 2025

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

FDA News

Pegcetacoplan's Approval & Shifting C3G Landscape, with Sayna Norouzi, MD

C3G treatment options expand with FDA approvals of pegcetacoplan and iptacopan, offering new hope for patient care.

Pegcetacoplan's Approval and Shifting C3G Landscape, with Sayna Norouzi, MD

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Implications of Findings on Roflumilast Cream 0.05% for Atopic Dermatitis, with Adelaide Hebert, MD

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Panelists discuss how esophageal dilation is an important therapeutic intervention for the fibrostenotic complications of eosinophilic esophagitis (EoE). They emphasize the need to treat inflammation first before dilation, using techniques such as balloon pull-through or Savary dilators depending on stricture location and severity, and the importance of achieving controlled mucosal disruption while being less aggressive than with peptic strictures to ensure safety and effectiveness.

Video Series

Utility of Esophageal Dilatation in EoE

A 4.5 mm cut-off using the Skin Prick Automated Test showed comparable accuracy to the standard skin prick test in detecting birch pollen and house dust mite allergies.


Automated Skin Prick Test at 4.5 mm Cut-Off Matches Accuracy of Traditional Method

Panelists discuss how dietary elimination therapy for eosinophilic esophagitis (EoE) involves empirically removing common food triggers (dairy, wheat, eggs, soy, seafood, nuts), with less restrictive approaches such as eliminating 1 to 2 foods being more feasible than the traditional 6-food elimination. The panelists emphasize the critical role of dieticians, avoiding combination therapies when possible, and allowing flexibility with “diet holidays” while monitoring for symptom recurrence.

Dietary Elimination Approaches in EoE

Check out expert perspectives and new research on hepatitis C, cirrhosis, and more in this July 2025 recap.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

6 Hepatology Headlines You Missed in July 2025

Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA) Geffen School of Medicine.

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Investigators believe this connection could be used to prognosticate and prevent future cases of diabetic retinopathy.

Interleukin-4 Correlated to Inflammation Regulation in Diabetic Retinopathy

The combination therapy of aflibercept and micropulsed yellow laser treatment results in good anatomical responses and substantially fewer intravitreal injections.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Latest News

5 Rheumatology Headlines You Missed in July 2025

From Misdiagnosis to Management: Understanding the Full Burden of MCS and FCS

Skin of Color Savvy: Improving Global Access in Dermatology with GLODERM

Dupilumab Reduces Food-Allergen sIgE in Children with Atopic Dermatitis

6 Rheumatology Headlines You Missed in July 2025